CorMedix announces preliminary unaudited financial results for Q4 and FY 2025, with net revenue of approximately $127 million and $310 million respectively.
The company expects clinical data from the Phase 3 ReSPECT study of REZZAYO in Q2 2026, and ongoing Phase 3 study of taurolidine/heparin catheter lock solution.
Introduction of FY 2026 Revenue guidance and operationalized synergies related to the acquisition of Melinta.
Financial Results
Q4 2025 net revenue of $127 million and FY 2025 net revenue of $310 million, with Pro Forma net revenue of $400 million.
Cash Holdings
Unaudited cash and short-term investments of approximately $148 million as of December 31, 2025.
Guidance for 2026
FY 2026 Revenue guidance of $300 million to $320 million, including $150 million to $170 million for DefenCath.
Operational Synergies
Management operationalized synergies of $35 million related to the acquisition of Melinta.
Analyst Day Announcement
CorMedix will hold an Analyst Day on February 10, 2026, to provide insights on its key pipeline assets and strategic direction.
- CorMedix achieved strong financial performance in 2025, exceeding revenue expectations.
- Expectations for clinical study outcomes in 2026 indicate potential for future growth.
- Guidance for 2026 and 2027 reflects strategic planning and forecasted revenue streams.
CorMedix has demonstrated significant growth potential with strong financial results and strategic initiatives. The company's focus on pipeline assets and operational efficiencies sets a promising trajectory for future success.